TREATMENT OF LATE-ONSET SYNDROMES SECONDARY TO NEUROLEPTICS

Remission rates for late onset syndromes a serious and disabling side effect of dopamine receptor blocking agents are low overall. An accurate phenomenological classification of these syndromes is needed to tailor treatment. The recommended treatment options have a low level of evidence. Clozapine has proven to be effective in clinical practice particularly in cases of resistant schizophrenia and late onset syndrome. Other therapeutic alternatives seem promising.